PLoS ONE (Jan 2019)

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.

  • Pirow Bekker,
  • Daniel Dairaghi,
  • Lisa Seitz,
  • Manmohan Leleti,
  • Yu Wang,
  • Linda Ertl,
  • Trageen Baumgart,
  • Sarah Shugarts,
  • Lisa Lohr,
  • Ton Dang,
  • Shichang Miao,
  • Yibin Zeng,
  • Pingchen Fan,
  • Penglie Zhang,
  • Daniel Johnson,
  • Jay Powers,
  • Juan Jaen,
  • Israel Charo,
  • Thomas J Schall

DOI
https://doi.org/10.1371/journal.pone.0210593
Journal volume & issue
Vol. 14, no. 1
p. e0210593

Abstract

Read online

[This corrects the article DOI: 10.1371/journal.pone.0164646.].